NCT02175433View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

October 14, 2014

Primary Completion Date

October 29, 2019

Study Completion Date

October 29, 2019

Conditions
Relapsed Lymphoid MalignancyRefractory Lymphoid Malignancy
Interventions
DRUG

AGS67E

intravenous (IV) infusion

Trial Locations (5)

10019

Site US0001, New York

66205

Site US0004, Fairway

91010

Site US0006, Duarte

94305

Site US0002, Stanford

V5Z 4E6

Site CA0005, Vancouver

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02175433 - A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies | Biotech Hunter | Biotech Hunter